The world urgently needs new antibiotics, yet the market routinely punishes companies that take on the long, risky and expensive work of developing them.

Economic reality and the persistent absence of funding stand in the way of using AI for antibiotic breakthroughs.

British immunotherapy company Centauri Therapeutics received a ₤6 million ($8.1 million USD) investment from the AMR Action Fund to support development of its broad-spectrum antibiotic candidate, CTX-...

AMR Action Fund CEO Henry Skinner, PhD, MBE, discusses the significance of this week, provides an update on the PASTEUR Act, and explains the differing approaches between Europe and the US with regard...

Researchers discovered a possible weakness in the deadly hospital superbug C. auris that could lead to new treatments for the drug-resistant fungal infection.

Scientists discover a gene capable of breaking down carbapenems, a class of powerful antibiotics seen as a drug of last resort

OPINION: The rise of antibiotic-resistant superbugs in California poses an enormous health threat — and we’re not doing nearly enough to address it, Henry Skinner writes.

Antimicrobial resistance (AMR) threatens lives, healthcare systems and the global economy. But anticipatory governance that reshapes responses can get ahead of the problem

Henry Skinner, PhD, CEO of the AMR Action Fund, reflects on how Russia’s invasion of Ukraine has exacerbated the issue of AMR.

Infections are the second leading cause of death among people with cancer, trailing only the cancer itself.

Henry Skinner, PhD, CEO of the AMR Action Fund, reflects on how Russia’s invasion of Ukraine has exacerbated the issue of AMR.

While men still account for about four in five cases, the infection rate among women has risen much faster in recent years.

Antimicrobial resistance (AMR) threatens lives, healthcare systems and the global economy. But anticipatory governance that reshapes responses can get ahead of the problem

Antibiotic resistance is one of the biggest health threats of our time—and tackling it will take more than a single breakthrough, writes Nicola Rose The Medicines and Healthcare Products Regulatory ...